Health · Pharma & Biotech · 3 hrs ago

Erasca data add pressure on Revolution Medicines’ cancer drug

Erasca data add pressure on Revolution Medicines’ cancer drug

Erasca’s data are adding pressure on Revolution Medicines’ cancer drug, Rasonque.

Rasonque is already off to one of the strongest oncology launches in history.

It is a targeted drug for pancreatic cancer, according to the information available.

Limitations with the drug leave room for competitors to try to address unmet needs.

Erasca is nearing the start of a Phase 3 trial, a later stage of testing.

The sources do not say when the trial will begin or what its results will show.

2 sources

Related